Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$1.38 - $2.84 $132,922 - $273,551
-96,321 Reduced 32.67%
198,544 $410,000
Q2 2022

Aug 05, 2022

BUY
$2.6 - $3.85 $766,649 - $1.14 Million
294,865 New
294,865 $952,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $171M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Granite Point Capital Management, L.P. Portfolio

Follow Granite Point Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Granite Point Capital Management, L.P. with notifications on news.